IRMD vs PRCT: stock comparison and AI forecast
Iradimed Corp (IRMD) and Procept Biorobotics Corp (PRCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IRMD Iradimed Corp
- Price
- $76.68 -8.1% · 6M
- Market Cap
- $981M
- P/E Ratio
- 41.9x
- Size
- small-cap
- AI Forecast
PRCT Procept Biorobotics Corp
- Price
- $19.44 -21.7% · 6M
- Market Cap
- $1.11B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- PRCT is 1.1 times larger than IRMD by market capitalization ($1.11B against $981M).
- Over the last six months IRMD returned -8.1% and PRCT -21.7%.
- IRMD turns 26.9% of its revenue into net income, against -32.5% for PRCT.
- PRCT carries 0.41 times debt per unit of equity, against 0.14 times for IRMD.
- IRMD yields 1.65% in dividends; PRCT pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IRMD | PRCT |
|---|---|---|
| Market Cap | $981M | $1.11B |
| P/E Ratio | 41.89x | – |
| P/B Ratio | 9.21x | 3.27x |
| Dividend Yield | 1.65% | – |
| EPS | $1.83 | $-1.84 |
| Book Value/Share | $8.33 | $5.94 |
| Revenue/Share | $6.99 | $5.89 |
| FCF/Share | $2.04 | $-1.48 |
Profitability & Margins
| Metric | IRMD | PRCT |
|---|---|---|
| ROE | 22.5% | -32.3% |
| ROA | 19.8% | -22.9% |
| ROIC | 26.1% | -27.5% |
| Gross Margin | 75.5% | 64.2% |
| Operating Margin | 32.3% | -33.9% |
| Net Margin | 26.9% | -32.5% |
| EBT Margin | 34.8% | -30.9% |
| Tax Rate | 22.9% | -0.2% |
Financial Health
| Metric | IRMD | PRCT |
|---|---|---|
| Current Ratio | 8.99x | 6.55x |
| Quick Ratio | 7.68x | 5.35x |
| D/E Ratio | 0.14x | 0.41x |
| Financial Leverage | 1.14x | 1.41x |
| Interest Coverage | – | -34.7x |
| Working Capital | $82M | $356M |
Cash Flow
| Metric | IRMD | PRCT |
|---|---|---|
| Operating Cash Flow | $27M | -$74M |
| Free Cash Flow | $26M | -$85M |
| Capital Spending | -$1M | -$11M |
| OCF Growth YoY | 8.6% | – |
| FCF Growth YoY | 77.2% | – |
| FCF/Sales | 29.3% | -25.2% |
| CapEx/Sales | 1.1% | 3.1% |
Operational Efficiency
| Metric | IRMD | PRCT |
|---|---|---|
| Asset Turnover | 0.74x | 0.70x |
| Receivables Turnover | 6.5x | 3.1x |
| Inventory Turnover | 1.6x | 1.6x |
| Fixed Assets Turnover | 3.7x | 10.6x |
| Days Sales Outstanding | 56 days | 116 days |
| Days Inventory | 225 days | 233 days |
| Payables Period | 40 days | 46 days |
| Cash Conversion Cycle | 241 days | 304 days |
Income Statement
| Metric | IRMD | PRCT |
|---|---|---|
| Total Revenue | $89M | $337M |
| Operating Income | $29M | -$114M |
| Net Income | $24M | -$110M |
| R&D Expense | $3M | $79M |
| SG&A Expense | $41M | $252M |
| Cost of Goods Sold | $22M | $121M |
Dividend & Shareholder Information
| Metric | IRMD | PRCT |
|---|---|---|
| Dividends Per Share | $1.27 | – |
| Payout Ratio | 69.4% | – |
| Shares Outstanding | 13M | 57M |
| Net Income Growth | 10.0% | – |
| EPS Growth | 19.6% | – |
IRMD vs PRCT: stock comparison and AI forecast
Which is bigger, IRMD or PRCT?
PRCT is 1.1 times larger than IRMD by market capitalization ($1.11B against $981M).
Which stock performed better over the last six months, IRMD or PRCT?
Over the last six months IRMD returned -8.1% and PRCT -21.7%.
Which one does Intratio's AI model rank higher, IRMD or PRCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.